Chadwick David, Marson Tony
School of Clinical Science, University of Liverpool, Liverpool, United Kingdom.
Epilepsia. 2007 Jul;48(7):1259-63. doi: 10.1111/j.1528-1167.2007.01086.x. Epub 2007 Apr 18.
The ILAE treatment guidelines for initial monotherapy emphasise the poor quality of information available to inform everyday clinical practice. Industry sponsored studies comparing antiepileptic drugs answer restricted licensing questions, rather than those relevant to the clinical community (patients, health professionals and founders of health care). The SANAD study, a pragmatic randomized clinical trial, offers a methodology to address some of these questions. It identifies lamotrigine as a cost-effective alternative to carbamazepine for the treatment of focal epilepsies, but confirms valproate as the most effective drug for the treatment of generalized or unclassified epilepsy.
国际抗癫痫联盟（ILAE）的初始单药治疗指南强调，用于指导日常临床实践的信息质量欠佳。制药行业资助的比较抗癫痫药物的研究回答的是关于受限许可的问题，而非与临床群体（患者、医疗专业人员和医疗保健创始人）相关的问题。SANAD研究是一项实用的随机临床试验，提供了一种方法来解决其中一些问题。该研究确定，拉莫三嗪是治疗局灶性癫痫的一种具有成本效益的替代卡马西平的药物，但证实丙戊酸盐是治疗全身性或未分类癫痫最有效的药物。
